# Vanta Bioscienc (NSE: VANTABIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/VANTABIO · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹17 Cr, it ranks 3674th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

Its return on equity was 0.5% in FY26. Promoters held 72.81% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹17 Cr |
| ROE | 0.5% (FY26) |
| ROCE | 1.5% (FY26) |
| Debt to equity | 1.8 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹2 Cr | −₹13 Cr |
| FY24 | ₹10 Cr | −₹9 Cr |
| FY23 | ₹6 Cr | −₹10 Cr |
| FY22 | ₹10 Cr | ₹0 Cr |
| FY21 | ₹10 Cr | ₹0 Cr |
| FY20 | ₹14 Cr | ₹1 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 72.81%
- Non-institutions: 27.19%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Desh Rakshak](https://app.pivotnow.in/stock/DESHRAK) | — | ₹19 Cr | — | — |
| [Nidan Lab](https://app.pivotnow.in/stock/NIDAN) | ₹12.65 | ₹18 Cr | — | — |
| [Venmax Drugs](https://app.pivotnow.in/stock/VENMAX) | — | ₹17 Cr | — | — |
| [Zenith Health](https://app.pivotnow.in/stock/ZENITHHE) | — | ₹17 Cr | — | — |
| [Family Care Hos](https://app.pivotnow.in/stock/FAMILYCARE) | — | ₹16 Cr | — | — |
| [Colinz Labs](https://app.pivotnow.in/stock/COLINZ) | — | ₹15 Cr | — | — |

## Questions and answers

### What is the market cap of Vanta Bioscienc?

Vanta Bioscienc's market capitalisation is ₹17 Cr (₹17 Cr) at the 22 Oct 2026 close, ranking 3674th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Vanta Bioscienc?

Return on equity was 0.5% in FY26 and return on capital employed was 1.5% in FY26 (consolidated figures).

### Is Vanta Bioscienc a debt-free company?

No. Vanta Bioscienc's debt-to-equity ratio was 1.8 in FY26, with total debt of ₹31 Cr.

### What is the shareholding pattern of Vanta Bioscienc?

As of 31 Mar 2026: promoters 72.81%, non-institutions 27.19%.

### Who are Vanta Bioscienc's competitors?

The listed Pharma & Healthcare companies closest to Vanta Bioscienc by market cap are Desh Rakshak, Nidan Lab, Venmax Drugs, Zenith Health, Family Care Hos and Colinz Labs.

### Is Vanta Bioscienc a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Vanta Bioscienc's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VANTABIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.